|Bid||27.25 x 0|
|Ask||27.28 x 0|
|Day's Range||27.22 - 29.33|
|52 Week Range||18.23 - 70.98|
|Beta (5Y Monthly)||3.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2020 - Feb 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.21|
CBC report says Ontario will open more stores, making it easier for licensed producers to get their product to consumers.
As promised, Constellation Brands (NYSE:STZ) brought one of its own executives to fill the CEO chair at Canopy Growth (NYSE:CGC), the cannabis company it invested in back in 2018.Source: Shutterstock Newly picked David Klein's mission is to oversee Cannabis 2.0, a line of beverages and edibles infused with pot that became legal in Canada this month. Former CEO Bruce Linton hailed Klein as "a perfect pick." Canopy shares are down 65% in just 7 months, leading analysts to ask whether it's hit a bottom, and whether they should buy it.Analysts agree. The short answer is no.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chocolate Save Us!The little town of Smiths Falls, Ontario, is celebrating the re-opening of its former Hershey's factory to produce Canopy Growth chocolates. A press release on the opening says Canopy is "poised to lead the industry in bean-to-bar cannabis-infused chocolate."Canopy says it can produce 850,000 chocolates per month with the ability to scale higher. Deloitte claims there's a $1.6 billion edibles market waiting. * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade Many of Canopy's new products go by the name of Tokyo Smoke. They will be infused with either THC, the ingredient in marijuana that gets people high, or CBD, the ingredient that is supposed to relieve pain. Wrong DaveNext month that celebration will be followed by the arrival of David Klein, formerly Constellation CFO, as Canopy's new CEO. He's the wrong Dave. The right Dave would be the one from the 50-year old Cheech & Chong sketch, the illegal pot dealer.That's because so far, legal pot has been getting squished by the illegal variety -- and that's the case everywhere it has been tried. Legalization has taken the heat off illegal growers and distribution channels.Illegal pot looks and tastes just like the legal stuff, and costs just half as much. It's also more widely available, because there are few stores. Once a bud is lit, cops can't tell whether it's legal. Busting personal use of marijuana is no longer a priority.The result is that legal growers, like Canopy Growth, have warehouses full of the stuff, which they can't move. Illegal growers are cleaning up. Stock's Too HighEven with its precipitous fall in price this year, Canopy Growth is still extremely dear.Over the last year, Canopy is down by one-third. But if you look at a two-year chart, it's still up 16%. The numbers still don't add up for anyone but the most ambitious speculator. The market capitalization on Dec. 13 is $7.3 billion, on sales for the first half of the year totaling $161 million.Even assuming a doubling of sales for the back-half of the fiscal year, thanks to edibles, which are only legal in Canada, you're paying 15 times revenue for a company that has lost nearly $1.9 billion over the last 12 months.What Canopy Growth really needs now are cops. Cops in Canada, in California and everywhere else where pot is legal, busting farms, tossing dealers in jail, interrupting illegal supply chains on behalf of the legal ones.That's not going to happen. The Bottom Line on Canopy GrowthMarijuana is much easier to grow than tobacco.The current legal price is too high to compete with the illegal market. This is especially true when there's no way to tell the difference between legal and illegal bud.Canopy's bet on Cannabis 2.0 won't pay off until the illegal market is exhausted, or smokers decide they need a more unobtrusive high. If profits are in sight, Constellation can buy the rest of the company for much less than it's trading at now.Dana Blankenhorn is a financial and technology journalist. He is the author of the historical mystery romance The Reluctant Detective Travels in Time, available now at the Amazon Kindle store. Write him at firstname.lastname@example.org or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this story. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade * 7 Tech Stocks to Stuff Your Stocking With * 7 Sinfully Good Casino Stocks That Could Win the Jackpot in 2020 The post Canopy Growth Needs You to Call the Cops appeared first on InvestorPlace.
There has been a comeback by marijuana stocks, but investors have been skeptical of the rally -- and rightfully so. It's hard to trust names like Cronos Group (NASDAQ:CRON) and Canopy Growth (NYSE:CGC) as they've been under incredible pressure. Who's to say we're not just seeing a dead cat bounce by CGC and CRON stock?Source: Shutterstock Many times, the difference between a true reversal and a dead cat bounce is only obvious in hindsight. However, investors who believe in the long-term potential of these businesses may consider it too hard to pass up these stocks when they are down 60%-plus from their highs.Is CRON a good stock to buy? Let's take a look.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evaluating Cronos Group StockI've said it before and I'll say it again: Cannabis stocks are very hard to evaluate. They command huge valuations relative to their current sales, and they are generally unprofitable and cash flow negative. Those are not the types of investments that most people seek out.However, investors do look for companies with plenty of opportunity, which pot stocks happen to have.CRON had a 237% year-over-year revenue gain in its most recent reported quarter. But here's where things get tough. The company had revenue of just 12.7 million CAD last quarter. In the first three quarters of its current fiscal year, CRON stock had just 29.4 million CAD of sales. Nonetheless, Cronos stock has a market cap of $2.4 billion.Marijuana stocks have extremely high valuations for two reasons: The large investments some cannabis companies have received from corporations and their large potential market. Unfortunately, the latter hasn't panned out quite as well as many had hoped. * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade I think investors would shrug off the valuation concerns if marijuana stocks could live up to the growth hype. CRON stock is a great example, as it's missed average revenue expectations in five of the last six quarters. Even though its growth is strong, it's not growing as rapidly investors had hoped for.Thankfully, Cronos Group has a decent balance sheet.The company has total cash of $1.99 billion. While that's down from $2.4 billion just two quarters ago -- and that is a little concerning -- it still has plenty in the bank.Cronos' current liabilities of $614 million is roughly 29% the size of its current assets, which stand at $2.08 billion. Its total assets of $2.76 billion also easily outweigh its total liabilities of $615 million. The biggest issue for Cronos stock is cash burn. If CRON was reporting break-even cash flow, it would be a lot easier to bet on its business. Trading CRON Stock Click to Enlarge Source: Chart courtesy of StockCharts.comSometimes a picture -- or in the case, a chart -- says 1,000 words. One glance at CRON stock over the last three quarters tells investors everything they need to know about what's been going on. To add insult to injury in the case of cannabis stocks, the overall market has been making new high after new high.So what will happen going forward?As the headline of my column states, CRON stock has been capped by downtrend resistance (depicted by the blue line on the chart above). Cronos stock has been below the 50-day moving average for the last five to six months. In order for bulls to garner any type of upside momentum, this pattern must stop.That is, CRON stock has to get above its downtrend resistance and the 50-day moving average. On the plus side, the stock's early December pullback did not result in a new low.Cronos Group stock has a 52-week low of $6.04. If CRON stock breaks below that, bulls' backs would be broken. I would love to see the stock continue to make higher lows going forward,and to take out its downtrend resistance and the 50-day moving average. If it can do so, the $8 level should be watched. Above that, and the shares may really start to garner some momentum.Keep in mind that end-of-the-year selling spurred by the desire to take losses for tax purposes may keep pressure on marijuana stocks. But if CRON stock can avoid making new lows in 2019, it may have an opportunity to rally in 2020.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade * 7 Tech Stocks to Stuff Your Stocking With * 7 Sinfully Good Casino Stocks That Could Win the Jackpot in 2020 The post Can Cronos Stock Break Out of Its Downtrend? appeared first on InvestorPlace.
It has been a rough ride for shares of Canadian cannabis producer Aurora Cannabis (NYSE:ACB) in 2019. Aurora began the year priced around $5. However, it's exiting the year at around half of that value -- mostly thanks to stagnant revenue growth amid challenging demand trends in its core Canadian consumer market.Source: Shutterstock But, I think that 2020 is shaping up to be a great year for Aurora Cannabis.The contrarian bull thesis here is simple. Those challenging demand trends in the Canadian consumer market will turn around in 2020. This is due to the launch of new products like edibles and vapes, a reduction in legal channel supply constraints and an expanded retail distribution footprint.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs those demand trends turn around, Aurora's revenue growth will re-accelerate higher. This resurgence, coupled with favorable U.S. legislation progress, will spark a big rebound for Aurora. * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade As such, although it's easy to write off Aurora Cannabis as a falling knife at this point. I ultimately think that dip buyers who exercise patience at these levels will be rewarded in a big way over the next 12 months. The Canadian Cannabis Market Will Bounce BackThe Canadian cannabis market looks poised for a big rebound in 2020 after a rough 2019.The big problem with the Canadian cannabis market in 2019 was that consumer demand in the legal channel fell flat. That happened for a number of reasons, all of which come back to this idea that the legal channel failed to pull that much demand from the black market.That said, the black market had lower prices because they didn't have to pay legal or regulatory fees. They also didn't have any supply issues -- whereas nascent legal suppliers had huge supply constraints. They were also able to get product to consumers in a timely manner -- whereas legal suppliers were still learning the ropes of cannabis distribution and logistics -- and offered a wider array of products that legal suppliers couldn't sell.Fortunately for those interested in investing in the Canadian cannabis market, all of that will change in 2020.First, that Canadian government is aware that the black market is outpricing the legal market, and there appears to be legal steps being made to rectify this issue. Second, legal suppliers have spent all of 2019 increasing growing capacity. So, come 2020, there should be no more supply constraints. Third, legal suppliers are also aggressively expanding their retail footprint throughout Canada, and that should lead to improved logistics. Fourth, the legal market will able to sell cannabis 2.0 products like vapes and edibles in 2020.Therefore, 2019 cannabis market demand headwinds should turn into 2020 demand tailwinds. As they do, everything will improve for cannabis companies. Revenue growth rates will ramp back up, margins will improve and net losses will shrink.As all those things happen, pot stocks should bounce back. It also doesn't hurt that the U.S. is inching towards federal legalization of cannabis with the House Judiciary Committee recently passing the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act. Aurora Will Bounce Back, TooAs the cannabis sector bounces back in 2020, Aurora will bounce back, too.I like Aurora Cannabis in the cannabis sector for a few, very simple reasons. First, the company is very big in this world. They are second to only Canopy Growth (NYSE:CGC) in terms of sales and growing capacity. After those two, it's a steep drop off to the rest of the pack.Second, they have a strong leadership position in the markets in which they operate. In the Canadian consumer market, Aurora owns the top three best-selling cannabis consumer products in Ontario -- Pink Kush, Blue Dream and Tangerine Dream. Internationally, the company has a leadership position in medical marijuana throughout most of Europe.Third, Aurora is supported by favorable margin trends. Gross margins here are high for the cannabis industry, up near 60% last quarter. Those gross margins are also stable, and haven't changed in several months. At the same time, management is exercising disciplined cost control, while selling, general and administrative expenses dropped 1% quarter-over-quarter last quarter.Fourth, the valuation on Aurora is favorable relative to other pot stocks. Aurora's market cap presently stands at $2.7 billion. Revenue estimates for two years ahead stand around $950 million. That gives Aurora Cannabis a two-year-forward sales multiple of less than 3. Peers Canopy Growth, Tilray (NASDAQ:TLRY), and Cronos (NASDAQ:CRON) all trade north of four-times sales that are two years out.All in all, there are a lot of positives which make Aurora stand out in the cannabis sector in a good way. Those positives ultimately mean that if the cannabis sector rebounds in 2020, Aurora could rebound by even more. Bottom Line on Aurora CannabisYes, Aurora looks like a falling knife. In 2019, it was. But, in 2020, it won't be.Instead, Aurora's awful 2019 performance actually sets the stock up nicely for a big 2020 rebound amid a significant reversal in Canadian consumer market demand trends.As such, I think patience will be rewarded here. There's no need to rush and buy the dip just yet. Instead, be patient. Wait for signs that the turnaround is emerging. Then, buy the dip and hold for the big 2020 rally.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Worst Dividend Stocks of the Decade * 7 Game-Changing Tech Stocks to Buy Now * 5 Chinese Stocks to Buy for the Big 2020 Rebound The post Patience With Aurora Cannabis Will Pay Off in 2020 appeared first on InvestorPlace.
Cannabis stocks rallied out of the gate Friday, after a report that the Canadian province of Ontario will open up the market for retailers with plans to issue abut 20 new store approvals starting in April of 2020. The news reported by Canadian network CBC eased concerns about the shortage of stores that has hampered the development of the legal cannabis market in Canada and allowed the black market to continue to thrive. "This is certainly better than the status quo," said MKM analyst Bill Kirk. "In the fight to take share from the illicit market (which has ~80% share), access to stores has been a major issue." he cautioned, however, that access is not the only obstacle the market is facing, highlighting quality and price as other major issues. A survey conducted by MKM found Canadian consumers using the black market due to price convenience and also quality. "Further, Canopy teased an expectation for 40 Ontario stores per month beginning in January," said Kirk. "If the details of 20 store/month beginning in April hold true, Ontario would have 62% fewer stores by year-end 2020 than Canopy had expected (480 vs 180). All else being equal, we would recommend selling into any strength this news may produce." Canopy shares rose 5%, Aurora Cannabis was up 5.2%, Cronos was up 3% and Tilray rose 2.5%. MedMen rose 11%, Aleafia rose 5% and Organigram added 5%.
Alcoholic beverage giant Constellation Brands has a large stake in Canadian cannabis company Canopy Growth, which is producing big losses.
The past six months haven't been great for Aphria (NYSE:APHA), but shares haven't fallen as far as the company's more famous peers. Aphria stock is down 27.7% in the past six months. In contrast, the more popular "pot stocks" are down much more. Shares in Aurora Cannabis (NYSE:ACB) dropped 66.5% in the same period. Hexo (NYSE:HEXO) has fallen 61%. Canopy Growth (NYSE:CGC) is down 50.9%.Source: Shutterstock Why hasn't APHA stock performed as badly? Perhaps it's because Aphria has historically traded at a discount to its competitors. Back in September, Aurora, Canopy, and Hexo were trading at enterprise value/sales (EV/Sales) ratios north of 30. At the same time, Aphria's EV/Sales was just 9.5.Today, Aphria trades at an EV/Sales ratio of 6.7. While it is by no means a "value stock," APHA remains a relative bargain.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDoes this mean its time to buy? Let's take a closer look. Growth is priced into shares, but this overlooked pot stock could be a diamond in the rough. Aphria Marches Towards ProfitabilityAPHA may be an also-ranb pot stock, but the company is no slouch when it comes to market share. Aphria has supply agreements across all of Canada's provinces. This gives them access to 99.8% of the country's population. * The 10 Worst Dividend Stocks of the Decade Oversupply in Canada is an issue, yet Cannabis 2.0 could spur demand. But unlike Canopy or Hexo, Aphria has not announced a big infused beverage launch. Yet, Aphria does have Cannabis 2.0 exposure. Back in June, the company announced a partnership with Pax Labs to develop cannabis vape products.Over in Europe, Aphria is betting big on medical marijuana. Especially in Germany. The company is one of just three to obtain a cultivation license there. The company's German unit CC Pharma is the biggest piece of the Aphria pie, making up 74% of net revenues. Aphria is also a big player in Latin America, via its acquistion of LATAM Holdings.The company's peers are hemorrhaging cash. But Aphria stock posts quarterly positive EBITDA. The company's strategy appears to be paying off. But why does Aphria continue to trade at a low valuation? Why is APHA Stock So Cheap?Aphria trades at a sharp discount to peers. As I mentioned above, Aphria's current EV/Sales ratio is 6.7. In contrast, Aurora Cannabis has an EV/Sales ratio of 14. Hexo also trades at an EV/Sales ratio of 13. Canopy's EV/Sales ratio is 21.9.But there is a reason behind the discount. Aphria has a bad reputation among investors. Prominent short-seller Hindenburg Research lambasted the company in December 2018. This was due to accusations some Aphria insiders engaged in self-dealing. Aphria has been able to salvage its reputation after a management shakeup, but Wall Street still gives Aphria a skeptical eye.Aphria's strong balance sheet ought to counter this. The company has $348.8 million in cash and short-term investments. Aphria does have an equally-sized debt load ($356 million). But as InvestorPlace's Ian Bezek recently pointed out, Aphria has no problems obtaining credit.Competitors have had more trouble raising capital. Yet Aphria was able to obtain attractive financing for its Diamond production facility. Aphria lacks a strategic partner like Constellation Brands (NYSE:STZ) or Altria Group (NYSE:MO). But the company has avoided the capital crunch seen with Aurora. The Bottom Line on Aphria StockAphria stock has a clear path to profitability. Yet, shares trade at a discount to peers. Past scandals continue to tarnish the stock. But for investors playing at home, run the numbers. The company has more going for it than Wall Street gives credit.But does this make APHA stock a buy today? Perhaps. Analyst consensus projects positive earnings-per-share in 2020 and 2021. Meanwhile, names like Aurora and Canopy will remain unprofitable. The bigger names dominate the headlines. But under-the-radar Aphria may be the best "pot stock" buy.I remain on the fence with regards to pot stocks. I'm waiting for valuations to fall to more reasonable levels. But if you have pot stock FOMO and worry today's prices will be a bargain in hindsight, consider APHA.As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Worst Dividend Stocks of the Decade * 7 Game-Changing Tech Stocks to Buy Now * 5 Chinese Stocks to Buy for the Big 2020 Rebound The post Consider Aphria Stock as the Cannabisphere Burns appeared first on InvestorPlace.
/R E P E A T -- Media Advisory - Canopy Growth Brings Chocolate Back to Smiths Falls: Official Chocolate Factory Ribbon Cutting/
Hagens Berman urges Canopy Growth Corporation (NYSE: CGC) investors who have suffered losses in excess of $500,000 to submit their losses now to learn if they qualify to recover compensable damages. A new class action complaint has been filed against the company and senior executives, extending the fraudulent period back to Sept. 8, 2018.
Canopy Growth Corporation, USA, LLC (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") today announced the launch of First & Free – a hemp-derived CBD product line offered in a variety of formats, including softgels, oil drops and creams. The products will be available for purchase on the company's first e-commerce site: www.firstandfree.com.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Lipocine, Inc. (NASDAQ: LPCN), Armstrong Flooring, Inc (NYSE: AFI), Wanda Sports Group Company Limited (NASDAQ: WSG), and Canopy Growth Corporation (NYSE: CGC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Media Advisory - Canopy Growth Brings Chocolate Back to Smiths Falls: Official Chocolate Factory Ribbon Cutting
Cannabis stocks fell Tuesday, as analysts weighing in on Canopy Growth’s new chief executive took a cautious stance, highlighting the continuing challenges facing the company.
Stocks wavered on Tuesday, as reports signaled that the U.S. may not apply new tariffs on China on December 15th. Still, equities were mixed as a bevy of headlines continue to hit the wires. Let's look at a few top stock trades in the meantime. Top Stock Trades for Tomorrow No. 1: Canopy Growth (CGC)Source: Chart courtesy of StockCharts.comWe've looked at the daily charts a number of times for Canopy Growth (NYSE:CGC). Let's look at a weekly one instead.Investors can see how $15 played a vital role during last month's meltdown, just as the 200-week moving average is now playing a role as resistance. $22.50 has also acted as a ceiling on CGC.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOn the plus side, shares are above the 10-week moving average and downtrend resistance (blue line), the latter of which has been in play since summer. * 10 Best-Performing Growth Stocks of the 2010s So what now? I'd love to see a move over $22.50, which could trigger a longer-term breakout. On the downside, let's see if shares can stay above $17.50. Moving below that level puts the $15 level back on watch. Top Stock Trades for Tomorrow No. 2: Dave & Buster's (PLAY)Source: Chart courtesy of StockCharts.comI'm also using a weekly chart for Dave & Buster's (NASDAQ:PLAY). After getting hammered from $50 down to $40 in June, shares have been consolidating between $37.50 and $42.50.That's a relatively tight range, but it also sets up an excellent trading scenario. Over $42.50 opens the door to PLAY's major moving averages, between $45 and $48. Above the latter and downtrend resistance (blue line) near $52 is in play.On the downside, a move below $37.50 could send shares down into no man's land. There's a multi-year low down near $29, with a Fibonacci extension near $32. Top Stock Trades for Tomorrow No. 3: MongoDB (MDB)Source: Chart courtesy of StockCharts.comMongoDB (NASDAQ:MDB) shares were initially higher after reporting earnings, but those morning gains have since evaporated. In fact, the price action has turned rather ugly on Tuesday.The stock opened at $144.77, ticked higher by three cents, then plunged lower throughout the session. In doing so, MDB knifed right through its 20-day, 50-day and 200-day moving averages.It's really not a good look.Now, shares face the backside of prior downtrend resistance. If it holds as support, see if MDB can reclaim its major moving averages on the upside. If it can, it puts $145-plus back on the table.Should support fail to hold, look for a possible test of $115. That area was clear support in September and October. Below there, MDB could fill its gap down toward $105. Top Stock Trades for Tomorrow No. 4: Peloton (PTON)Source: Chart courtesy of StockCharts.comPeloton (NASDAQ:PTON) just can't seem to stay out of the news. This time, it's as Citron takes a swing at the stock, assigning a 2020 price target of $5.For now, PTON continues to put in higher lows (blue line), while struggling with $35. Above $35 could trigger a breakout to $37, where it faces its former highs. Above that and $40 is on the table.Below uptrend support and the 20-day moving average will be bulls' next line of defense. Below that and the $29 IPO price is on the table. Top Stock Trades for Tomorrow No. 5: GameStop (GME)Source: Chart courtesy of StockCharts.comGameStop (NYSE:GME) has really struggled this year, but the damage was a lot worse in August when shares hit a low of $3.15.The company will report earnings on Tuesday after the close. Ahead of the results, shares are struggling with the 200-day moving average, while maintaining above the 50-day moving average.The setup now is simple: Moving over the 200-day moving average could squeeze shares up toward $7.75 to try and fill the June gap. A move below the 50-day at $5.89 could send shares to $5, a pivotal level over the last six months.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best-Performing Growth Stocks of the 2010s * 10 Stocks With Little or No Debt to Own for the Next 50 Years * 5 Restaurant Stocks Dominating Holiday Season Foot Traffic The post 5 Top Stock Trades for Wednesday: CGC, PLAY, MDB appeared first on InvestorPlace.
Constellation Brands Chief Financial Officer David Klein will be Canopy Growth’s next CEO. But that doesn’t mean it’s time to buy the stock, according to an analyst at MKM Partners.
Canopy Growth Corp. said Monday it has named David Klein, currently chief financial officer at its biggest shareholder, Constellation Brands Inc., as its new chief executive, taking over from Mark Zekulin on January 14.
STOCKSTOWATCHTODAY BLOG Three numbers to start your day: Paul Volker Was 92 When he Passed Away on Sunday Volker was the former chairman of the Federal Reserve and a towering figure in finance. He famously took over America’s central bank in 1979 when inflation was well past double digits and managed to tame price increases.
Even after being fired as Canopy Growth's co-CEO earlier this year, Bruce Linton is applauding the company's pick to replace him.
Canopy Growth soared Monday on the news Constellation Brands CFO David Klein will become CEO of the troubled Canadian cannabis producer.
Canopy Growth shares are surging today, after the cannabis giant announced it has landed a new CEO. Former Canopy Growth Co-CEO and Vireo Health Executive Chairman Bruce Linton joins Yahoo Finance's Zack Guzman and Brian Cheung, along with Campus Reform Editor-in-Chief Cabot Phillip, to discuss the company's leadership shakeup and more.